Exagen (FRA:E08A) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:E08A Exagen Inc FRA:E08A
56 GF Score
Price €5.85
GF Value €2.85
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Exagen Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

FRA:E08A
56GF Score
Exagen Inc FRA:E08A
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Exagen (FRA:E08A) Overvalued in 2026?

Based on GuruFocus' analysis, Exagen stock appears to be overvalued. The current stock price of €5.85 is trading 105.3% above its estimated GF Value™ of €2.85. GuruFocus considers Exagen to be Significantly Overvalued.

Key valuation signals for FRA:E08A:

  • Dividends Received:
  • GF Value™: €2.85 vs. price of €5.85 (105.3% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the FRA:E08A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Exagen Business Description

Other Exchanges XGN:USA
Address 1261 Liberty Way, Vista, CA, USA, 92081
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
56GF Score

Get the complete analysis for FRA:E08A

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.85
Price
€2.85
GF Value